Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sympathetic Mechanisms in Obesity-Crossover Design
Sponsor: Vanderbilt University Medical Center
Summary
We will study obese hypertensive subjects in a randomized, crossover study to determine if two weeks sympathetic blockade improves endogenous glucose production. Subjects will be studied on 3 different occasions after two weeks of receiving either placebo, amlodipine (vasodilator arm) or moxonidine (study arm). The order of the studies will be determined using computer-generated randomization. Patients will be blinded as to which treatment they are receiving on each day. An investigator blinded to the treatment assignment will perform the analysis of the data.
Official title: Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity, Crossover Design Study.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2022-05-20
Completion Date
2030-12-31
Last Updated
2026-02-27
Healthy Volunteers
No
Conditions
Interventions
Amlodipine
Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.
Moxonidine
Moxonidine
Placebo
Placebo
Locations (1)
Vanderbilt University Medical Center
Nashville, Tennessee, United States